These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36271897)

  • 61. Open ADAMTS-13 conformation index predicts earlier relapse in immune-mediated thrombotic thrombocytopenic purpura.
    De Waele L; Sakai K; Mancini I; Sinkovits G; Falter T; Inoue T; Agosti P; Rossmann H; Von Auer C; Tersteeg C; De Meyer SF; Joly BS; Veyradier A; Coppo P; Fijnheer R; Peyvandi F; Prohászka Z; Lämmle B; Vanhoorelbeke K
    J Thromb Haemost; 2024 Feb; 22(2):493-502. PubMed ID: 37866519
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP).
    Shah N; Rutherford C; Matevosyan K; Shen YM; Sarode R
    Br J Haematol; 2013 Nov; 163(4):514-9. PubMed ID: 24111495
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Management of immune thrombotic thrombocytopenic purpura with caplacizumab: a Canadian, single-centre, real-world experience.
    Tse B; Buchholz M; Pavenski K
    Platelets; 2023 Dec; 34(1):2157807. PubMed ID: 36636834
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature.
    Yomtovian R; Niklinski W; Silver B; Sarode R; Tsai HM
    Br J Haematol; 2004 Mar; 124(6):787-95. PubMed ID: 15009067
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Thrombotic thrombocytopenic purpura in children.
    Loirat C; Coppo P; Veyradier A
    Curr Opin Pediatr; 2013 Apr; 25(2):216-24. PubMed ID: 23422353
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Thrombotic Thrombocytopenic Purpura: Beyond Empiricism and Plasma Exchange.
    Tsai HM
    Am J Med; 2019 Sep; 132(9):1032-1037. PubMed ID: 30928346
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [A combined regimen based on bortezomib and glucocorticoids for 6 patients with recurrent/refractory immune thrombotic thrombocytopenic purpura].
    Yin J; Tian H; Kong DQ; Li Y; Gu CY; Wu DP; Yu ZQ
    Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):413-417. PubMed ID: 37550192
    [No Abstract]   [Full Text] [Related]  

  • 68. Plasma Cell Directed Therapy for Immune Thrombotic Thrombocytopenic Purpura (iTTP).
    Chen M; Shortt J
    Transfus Med Rev; 2022 Oct; 36(4):204-214. PubMed ID: 36396570
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.
    Scully M; Cohen H; Cavenagh J; Benjamin S; Starke R; Killick S; Mackie I; Machin SJ
    Br J Haematol; 2007 Feb; 136(3):451-61. PubMed ID: 17233847
    [TBL] [Abstract][Full Text] [Related]  

  • 70. ADAMTS13 and Non-ADAMTS13 Biomarkers in Immune-Mediated Thrombotic Thrombocytopenic Purpura.
    Bonnez Q; Sakai K; Vanhoorelbeke K
    J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834813
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease were significantly improved by rituximab treatment.
    Kameda T; Dobashi H; Kittaka K; Susaki K; Yamaoka G; Arai K; Tokuda M; Ishida T
    Clin Rheumatol; 2007 Dec; 26(12):2159-2162. PubMed ID: 17562094
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura.
    Gómez-Seguí I; Pascual Izquierdo C; de la Rubia Comos J
    Expert Rev Hematol; 2021 Aug; 14(8):707-719. PubMed ID: 34275393
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Clinical study on Rituximab in the treatment of idiopathic thrombotic thrombocytopenic purpura].
    Wang J; Wu T; Shen H; Ren C; Chen H; She Z; Wang Z
    Zhonghua Xue Ye Xue Za Zhi; 2015 Apr; 36(4):316-20. PubMed ID: 25916294
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Maintenance rituximab for relapsing thrombotic thrombocytopenic purpura: a case report.
    Saleem R; Rogers ZR; Neunert C; George JN
    Transfusion; 2019 Mar; 59(3):921-926. PubMed ID: 30548440
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pediatric thrombotic thrombocytopenic purpura.
    Joly BS; Coppo P; Veyradier A
    Eur J Haematol; 2018 Oct; 101(4):425-434. PubMed ID: 29889319
    [TBL] [Abstract][Full Text] [Related]  

  • 76. How I treat immune-mediated thrombotic thrombocytopenic purpura after hospital discharge.
    Akwaa F; Antun A; Cataland SR
    Blood; 2022 Aug; 140(5):438-444. PubMed ID: 35667044
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Current and Future Perspectives on ADAMTS13 and Thrombotic Thrombocytopenic Purpura.
    Roose E; Joly BS
    Hamostaseologie; 2020 Aug; 40(3):322-336. PubMed ID: 32726827
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura.
    Coppo P; Veyradier A
    Presse Med; 2012 Mar; 41(3 Pt 2):e163-76. PubMed ID: 22265954
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Successful treatment with cyclosporine in a patient with rituximab-refractory thrombocytopenic purpura].
    Nato Y; Nagaharu K; Okano M; Suzuki K; Matsumoto T; Tawara I
    Rinsho Ketsueki; 2021; 62(3):176-179. PubMed ID: 33828010
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Refractory thrombotic thrombocytopenic purpura achieving complete remission with rituximab treatment].
    Iino H; Ogawa Y; Yanagisawa K; Shimizu H; Mitsui T; Ishizaki T; Hayakawa M; Matsumoto M; Nojima Y; Handa H
    Rinsho Ketsueki; 2017; 58(3):204-209. PubMed ID: 28381686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.